Abstract:Objective: This study aimed to investigate the roles and mechanisms of action of tenofovir alafenamide fumarate (TAF)/tenofovir disoproxil fumarate (TDF) in liver fibrosis treatment.Methods: The effects of TAF/TDF on carbon tetrachloride (CCl4)-induced liver fibrosis in C57BL/6 wild-type or nonstructural protein 5A transactivated protein 9 (NS5ATP9) knockout mice were studied. The differentiation, activation, and proliferation of LX-2 cells after TAF/TDF treatment were tested in vitro. The expression of NS5ATP9 and activities of transforming growth factor-β1 (TGFβ1)/sekelsky mothers against Decapentaplegic Homolog 3 (Smad3) and NF-κB signaling pathways were detected in TAF/TDF-treated mice and LX-2 cells. The genes related to extracellular matrix accumulation were detected in vivo and in vitro after NS5ATP9 silencing or knockout.Results: TAF/TDF significantly inhibited CCl4-induced liver fibrosis in mice and regulated the differentiation, activation, and proliferation of hepatic stellate cells (HSCs). Furthermore, TAF/TDF suppressed the activities of TGFβ1/Smad3 and NF-κB signaling pathways in vivo and in vitro. NS5ATP9 inhibited liver fibrosis through TGFβ1/Smad3 and NF-κB signaling pathways. TAF/TDF upregulated the expression of NS5ATP9 in vivo and in vitro. Finally, TAF/TDF could only show marginly therapeutic effects when NS5ATP9 was silenced and knocked out in vivo and in vitro.Conclusions: TAF/TDF prevented progression and promoted reversion of liver fibrosis through assembling TGFβ1/Smad3 and NF-κB signaling pathways via upregulating the expression of NS5ATP9. TAF/TDF also regulated the differentiation, activation, and proliferation of HSCs. The findings provided strong evidence for the role of TAF/TDF as a new promising therapeutic strategy in liver fibrosis.Funding Statement: This study was supported by the National Natural Science Foundation of China (No. 81470863 and No. 81670547), the National Key Research and Development Program of China (No. 2017YFC0908100 and No. 2017YFC0908104), the Beijing Municipal Administration of Hospitals (XMLX201711 to JC), the Beijing Municipal Administration of Hospitals’ Ascent Plan (DFL20151701), and the National Science and Technology Major Project 2017ZX10201201-002-004). Support was also provided by the Collaborative Innovation Center of Infectious Diseases and the Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, China.Declaration of Interests: The authors declare no competing interests.Ethics Approval Statement: All animal experiments were conducted according to the ethical rules.

TAF and TDF attenuate liver fibrosis through NS5ATP9, TGFβ1/Smad3, and NF-κB/NLRP3 inflammasome signaling pathways

TAF and TDF Attenuate Liver Fibrosis Through NS5ATP9, TGFβ1/Smad3, and NF-κB Signaling Pathways

TAK-242 Ameliorates Hepatic Fibrosis by Regulating the Liver-Gut Axis

Tenofovir Alafenamide Fumarate Attenuates Bleomycin-Induced Pulmonary Fibrosis by Upregulating the NS5ATP9 and TGF-β1/Smad3 Signaling Pathway.

Liver Fibrosis Therapy Based on Biomimetic Nanoparticles Which Deplete Activated Hepatic Stellate Cells.

Tenofovir disoproxil fumarate directly ameliorates liver fibrosis by inducing hepatic stellate cell apoptosis via downregulation of PI3K/Akt/mTOR signaling pathway

Potential Molecular Targets of Tenofovir Disoproxil Fumarate for Alleviating Chronic Liver Diseases via a Non-Antiviral Effect in a Normal Mouse Model

The Antihepatic Fibrotic Effects of Fluorofenidone Via Mapk Signalling Pathways

Lactoferrin as a therapeutic agent for attenuating hepatic stellate cell activation in thioacetamide-induced liver fibrosis

The antiviral drug tenofovir, an inhibitor of Pannexin-1-mediated ATP release, prevents liver and skin fibrosis by downregulating adenosine levels in the liver and skin

TDF and TAF inhibit liver cancer cell migration, invasion via p7TP3

Axitinib attenuates the progression of liver fibrosis by restoring mitochondrial function

Targeting Follistatin like 1 ameliorates liver fibrosis induced by carbon tetrachloride through TGF-β1-miR29a in mice

Fluorofenidone alleviates liver fibrosis by inhibiting hepatic stellate cell autophagy via the TGF-β1/Smad pathway: implications for liver cancer

Fluorofenidone Affects Hepatic Stellate Cell Activation in Hepatic Fibrosis by Targeting the TGF-β1/Smad and MAPK Signaling Pathways.

WITHDRAWN: NS3TP1 promotes liver fibrosis by activating HSCs through TGFβ1/Smad3 and NF-κB/NLRP3 inflammasome signaling pathways

TJ-M2010-5, A self-developed MyD88 inhibitor, attenuates liver fibrosis by inhibiting the NF-κB pathway

Knockdown of N-acetylglucosaminyl transferase V ameliorates hepatotoxin-induced liver fibrosis in mice.

TDF and TAF inhibit hepatocellular carcinoma cell migration, invasion via p7TP3

DNMT3a-mediated methylation of TCF21/hnRNPA1 aggravates hepatic fibrosis by regulating the NF-κB signaling pathway

Tianhuang formula ameliorates liver fibrosis by inhibiting CCL2-CCR2 axis and MAPK/NF-κB signaling pathway